Torisel (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Date: March 31, 2012
Pages: 49
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Torisel (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Torisel (Renal Cell Carcinoma) - Analysis and Forecasts to 2022


GlobalData’s pharmaceuticals report, “Torisel (Renal Cell Carcinoma) - Analysis and Forecasts to 2022” provides Torisel sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2022). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Torisel including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Torisel including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2012-2022 for Torisel in the seven major markets

Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2012-2022 for all seven major markets


Torisel, sirolimus, Renal cell cancer, Wyeth Pharmaceuticals, enzyme inhibitor, first line treatment , sales forecast, Competition intensity

1.1 List of Tables
1.2 List of Figures


2.1 RCC
  2.1.1 Types of Renal Cell Carcinoma
2.2 RCC Market
2.3 Epidemiology
2.4 Pathophysiology
2.5 Etiology
  2.5.1 Cigarette Smoking
  2.5.2 Obesity
  2.5.3 Acquired Cystic Disease
  2.5.4 Hypertension
  2.5.5 Family History of Kidney Cancer
  2.5.6 High Blood Pressure
  2.5.7 Usage of Certain Medicines
  2.5.8 Advanced Kidney Disease
  2.5.9 Gender and Race
  2.5.10 Genetic and Hereditary Risk Factors
  2.5.11 Symptoms
  2.5.12 Diagnosis
2.6 GlobalData Report Guidance


3.1 RCC Disease Market
3.2 RCC Disease Market Forecasts and CAGR
3.3 Drivers for the RCC Disease Market
  3.3.1 High Incidence
  3.3.2 High Prevalence
  3.3.3 Emergence of Targeted Therapies
  3.3.4 Large Unmet Need
3.4 Tumor-Node-Metastases (TNM) Classification of RCC
  3.4.1 Staging
  3.4.2 Grading
  3.4.3 Prognosis
3.5 Treatment Options in RCC
  3.5.1 Surgery
  3.5.2 Radiation therapy
  3.5.3 Chemotherapy
  3.5.4 Targeted Therapies
  3.5.5 Tyrosine Kinase Inhibitors
  3.5.6 Mammalian Target of Rapamycin (mTOR) Inhibitor
  3.5.7 Vascular Endothelial Growth Factor (VEGF) Inhibitor
  3.5.8 Treatment by Stage
3.6 Classification of Patients with RCC


4.1 Introduction
4.2 Mechanism of Action
4.3 Clinical Studies
4.4 Approval History of Torisel
4.5 Factors Affecting Sales of Torisel
  4.5.1 Poor Efficacy
  4.5.2 Entry of Generics
  4.5.3 Use of Torisel in Second Line and Third Line Treatment
  4.5.4 Orphan Drug Status
4.6 Drug Evaluation
  4.6.1 Drug Risk Benefit Score
  4.6.2 Intensity of Competition
4.7 Sales Estimates
  4.7.1 Target Patient Pool of Torisel
  4.7.2 Dosing
  4.7.3 Market Penetration
  4.7.4 Annual Cost of Therapy
  4.7.5 Sales Projections of Torisel


5.1 Market Definitions
5.2 Abbreviations
5.3 Research Methodology
  5.3.1 Coverage
  5.3.2 Secondary Research
  5.3.3 Forecasting
  5.3.4 Number of Patients Approved to Take the Drug
  5.3.5 Net Penetration of Drug
  5.3.6 Net Annual Dosing
  5.3.7 Annual Cost of Therapy
5.4 Drug Sales Estimates Model
5.5 Contact Us
5.6 Disclaimer
5.7 Sources


Table 1: RCC, Incidences and Mortality, 2008-2030
Table 2: RCC, TNM Classification
Table 3: RCC, Fuhrman grading system
Table 4: RCC, Treatment Guidelines
Table 5: Torisel, RCC, Phase III Trial Results
Table 6: Torisel, RCC, Global, Approval History
Table 7: Torisel, RCC, Drug Risk Benefit Score
Table 8: Torisel, RCC, Global, Sales Estimates ($m), 2007-2014
Table 9: Torisel, RCC, Global, Sales Estimates ($m), 2015-2022
Table 10: Torisel, RCC, The US, Sales Estimates ($m), 2007-2014
Table 11: Torisel, RCC, The US, Sales Estimates ($m), 2015-2022
Table 12: Torisel, RCC, The UK, Sales Estimates ($m), 2007-2014
Table 13: Torisel, RCC, The UK, Sales Estimates ($m), 2015-2022
Table 14: Torisel, RCC, France, Sales Estimates ($m), 2007-2014
Table 15: Torisel, RCC, France, Sales Estimates ($m), 2015-2022
Table 16: Torisel, RCC, Germany, Sales Estimates ($m), 2007-2014
Table 17: Torisel, RCC, Germany, Sales Estimates ($m), 2015-2022
Table 18: Torisel, RCC, Italy, Sales Estimates ($m), 2007-2014
Table 19: Torisel, RCC, Italy, Sales Estimates ($m), 2015-2022
Table 20: Torisel, RCC, Spain, Sales Estimates ($m), 2007-2014
Table 21: Torisel, RCC, Spain, Sales Estimates ($m), 2015-2022
Table 22: Torisel, RCCJapan, Sales Estimates ($m), 2007-2014
Table 23: Torisel, RCC, , Sales Estimates ($m), 2015-2022


Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2010
Figure 2: Total number of cigarettes consumed, The US, 1976-2006
Figure 3: RCC, Global, Market Size Forecasts ($bn), 2010–2022
Figure 4: RCC, Global, Incidence (in million), 2008-2030
Figure 5: Oncology, Worldwide, Incidence (in million), 2008-2030
Figure 6: RCC, TNM Staging System
Figure 7: RCC, Marketed drug targets
Figure 8: RCC, Surgical Management
Figure 9: Treatment Algorithm for Metastatic Renal Cell Carcinoma
Figure 10: Classification of Patients with RCC
Figure 11: Torisel, RCC ,Drug Model Diagram
Figure 12: Torisel, RCC, Global, Sales Estimates ($m), 2007-2022
Figure 13 Torisel, RCC , The US, Sales Estimates ($m), 2007-2022
Figure 14: Torisel, RCC , The UK, Sales Estimates ($m), 2007-2022
Figure 15: Torisel, RCC, France, Sales Estimates ($m), 2002-2012
Figure 16: Torisel, RCC, , Germany, Sales Estimates ($m), 2007-2022
Figure 17: Torisel, RCC , Italy, Sales Estimates ($m), 2007-2022
Figure 18: Torisel, RCC , Spain, Sales Estimates ($m), 2007-2022
Figure 19: Torisel, RCC , Japan, Sales Estimates ($m), 2010-2022
Figure 20: Torisel, RCC, Global, Sales Distribution by Country (%), 2014
Figure 21: Patients Approved for the Drug
Skip to top

Ask Your Question

Torisel (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: